BeiGene, a Beijing company focused on novel oncology drugs, revealed plans to raise $126.5 million in an IPO on the NASDAQ exchange in early February.

Cocoon Networks of China set up shop in London with $707 million to fund innovative companies, including life science.

China's iCarbonX, a big data AI healthcare startup, is raising $106 million in initial funding.

CASI Pharma (CASI) with operations in the US and China, closed $10.3 million of a $25 million round.

Shanghai's WuXi Healthcare Ventures announced two investments in US biopharma companies.

Gedeon Richter, a Hungarian pharma, acquired 50% of its China JV from its partner.

Perennial Real Estate Holdings of Singapore plans to build integrated healthcare hubs in 20 to 40 Chinese cities.

Boston's NeuroMetrix received CFDA approval to market its diagnostic test for diabetic peripheral neuropathy in China.